Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

被引:0
作者
Alyssa I. Clay-Gilmour
Shaji Kumar
S. Vincent Rajkumar
Abdul Rishi
Robert A. Kyle
Jerry A. Katzmann
David L. Murray
Aaron D. Norman
Alexandra J. Greenberg
Dirk R Larson
Megan M. O’Byrne
Susan L. Slager
Celine M. Vachon
机构
[1] Mayo Clinic,Department of Health Sciences Research
[2] Mayo Clinic,Division of Hematology
[3] Mercy Hospital,Department of Internal Medicine
[4] Mayo Clinic,Department of Laboratory Medicine and Pathology
来源
Leukemia | 2019年 / 33卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.
引用
收藏
页码:499 / 507
页数:8
相关论文
共 278 条
  • [1] Rajan AM(2015)Interpretation of cytogenetic results in multiple myeloma for clinical practice Blood Cancer J 5 3-12
  • [2] Rajkumar SV(2011)The prognostic significance of cytogenetics and molecular profiling in multiple myeloma Cancer Genet 204 1234-42
  • [3] Sawyer JR(2011)Genomics in multiple myeloma Clin Cancer Res 17 1362-9
  • [4] Munshi NFlsd1C(2006)Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med 354 5412-7
  • [5] Avet-Loiseau H(2009)Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study Blood 113 933-42
  • [6] Kyle RA(2010)Prevalence of monoclonal gammopathy of undetermined significance: a systematic review Mayo Clin Proc 85 564-9
  • [7] Therneau TM(2002)A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 785-90
  • [8] Rajkumar SV(2009)Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance Blood 114 63-67
  • [9] Larson DR(1992)Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study Cancer Causes Control 3 551-4
  • [10] Plevak MF(1985)Multiple myeloma in a pair of monozygotic twins: the first reported case Br J Haematol 60 152-7